823,544 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 823,544 shares of the company's stock, valued at approximately $14,840,000. Connor Clark & Lunn Investment Management Ltd. owned 0.07% of Teva Pharmaceutical Industries as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of TEVA. Coronation Fund Managers Ltd. purchased a new position in shares of Teva Pharmaceutical Industries during the second quarter worth approximately $1,334,000. Point72 Asset Management L.P. boosted its holdings in shares of Teva Pharmaceutical Industries by 38.0% in the second quarter. Point72 Asset Management L.P. now owns 1,319,217 shares of the company's stock valued at $21,437,000 after acquiring an additional 363,217 shares in the last quarter. Lighthouse Investment Partners LLC acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter worth about $6,825,000. Ritholtz Wealth Management raised its holdings in Teva Pharmaceutical Industries by 269.5% during the third quarter. Ritholtz Wealth Management now owns 41,643 shares of the company's stock worth $750,000 after purchasing an additional 30,374 shares in the last quarter. Finally, Diversify Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $640,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Analyst Ratings Changes

TEVA has been the topic of several recent analyst reports. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, October 21st. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Finally, Barclays upped their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and a consensus price target of $19.67.

Teva Pharmaceutical Industries Stock Up 0.8 %

Shares of Teva Pharmaceutical Industries stock traded up $0.13 during trading on Thursday, reaching $17.16. The company had a trading volume of 487,176 shares, compared to its average volume of 9,194,461. The company has a market cap of $19.44 billion, a price-to-earnings ratio of -20.03, a price-to-earnings-growth ratio of 1.31 and a beta of 0.87. The firm's fifty day moving average is $17.72 and its 200-day moving average is $17.30. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. Teva Pharmaceutical Industries Limited has a fifty-two week low of $9.35 and a fifty-two week high of $19.31.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.